Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Zacks recently upgraded 2 small caps from Neutral to Outperform based on recent strategy execution by these companies which appears sustainable.
Fitlife Brands, Inc. is a provider of nutritional supplements serving the wellness and fitness markets. With a market cap of $153 m, Fitlife Brands, Inc. has $59 m of TTM sales. In Q2 Fitlife Brands grew revenue 14.7% YOY while adj. EBITDA grew 29%.
Gross Margin increased 480 bps YOY to 44.8% as higher margin online sales now comprise nearly two-thirds of revenue combined with effective cost optimization. Additionally, the company has been acquiring well-known brands and successfully rejuvenating them e.g. MusclePharm when incorporating them into their marketing ecosystem.
This asset light model with a high percentage of online sales is conducive to strong FCF (free cash flow). In our opinion, the strength in wellness and fitness trends appears sustainable. Anecdotally, I’ve been struck by the number of young athletes utilizing nutritional supplement products.
The stock is currently trading at 12.8X trailing 12-month EV/EBITDA TTM, which compares to 22.1X for the Zacks sub-industry, 13.5X for the Zacks sector and 14.7X for the S&P 500 Index. Over the past year, the stock has traded as high as 13.9X and as low as 10.1X, with a one-year median of 12.3X.
Source: Zacks Investment Research
Steel Partners Holdings L.P. is a diversified holding company focused on four segments: Diversified Industrial, Energy, Financial Services, and Supply Chain. Steel Partners has a market cap of $800 m with TTM sales of $1.9 B.
The Diversified Industrial segment manufactures engineered niche industrial products, including brazing alloys, stainless and low-carbon steel tubing, commercial construction materials, woven substrates for composite applications, power electronics, and specialized blades and films. This segment contributed 62.7% to the total revenues in 2023
Revenue grew 6.4% YOY in Q2 as weakness in the Energy segment was offset by strength in the other three segments. Q2 adj. EBITDA grew 13.8% YOY bolstered by the consolidation of its Supply Chain segment.
Most notably, the company has been able to reduce its debt from $191.4 m to $78.7 m over the last 6 months resulting in a material reduction in interest expense. Steel Partners Holdings also has $256.4 m in cash and cash equivalents.
The stock is currently trading at 1.28X trailing 12-month EV/EBITDA TTM, which compares to 14.44X for the Zacks sub-industry, 14.44X for the Zacks sector and 18.88X for the S&P 500 index.
Over the past five years, the stock has traded as high as 20.85X and as low as 1.04X, with a 5-year median of 3.97X.
Source: Zacks Investment Research
Zacks Investment Research
For Immediate Release
Chicago, IL – August 29, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. V, AstraZeneca PLC AZN, The Walt Disney Co. DIS, FitLife Brands, Inc. FTLF and Utah Medical Products, Inc. UTMD.
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Linde, AstraZeneca and Walt Disney Co.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. , AstraZeneca PLC and The Walt Disney Co. , as well as two micro-cap stocks FitLife Brands, Inc. and Utah Medical Products, Inc. . The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Visa have gained +4.6% over the year-to-date against the Zacks Financial Transaction Services industry’s gain of +7.9%. The company’s strategic acquisitions and alliances are fostering long-term growth and consistently driving its revenues. Visa, fueled by persistent increases in payments, cross-border volumes and sustained investments in technology, is witnessing significant profit growth.
The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value.
However, elevated operating expenses pose margin challenges. It is witnessing a volatile cash volume from the Asia Pacific and CEMEA regions. Consumer spending growth is also drying up. Moreover, rising client incentives will affect its adjusted revenues. As such, the stock warrants a cautious stance.
(You can read the full research report on Visa here >>>)
AstraZeneca’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+32.3% vs. +29.1%). The company has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra, Ultomiris and Farxiga should keep driving revenues.
AstraZeneca’s pipeline is strong, with important late as well as mid-stage pipeline data readouts lined up. It has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets.
Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. By 2030, it expects to generate $80 billion in total revenues. However, AstraZeneca’s diabetes franchise faces stiff competition while pricing pressure hurts sales in the respiratory unit.
(You can read the full research report on AstraZeneca here >>>)
Shares of Walt Disney have outperformed the Zacks Media Conglomerates industry over the year-to-date period (+0.3% vs. +0.1%). The company’s third-quarter fiscal 2024 results reflect growth in Disney+ subscribers and theme park and resort businesses.
Recent attractions like the Frozen theme land at Hong Kong Disneyland and Walt Disney Park in Paris, as well as the Zootopia theme land at Shanghai Disney, are expected to boost the prospects of the theme park business.
At the same time, the company’s declining ad revenues due to fewer impressions have been a headwind for some time now. Disney+’s profitability is expected to be hurt by higher investments in content, which will also increase programming and production costs in the Media and Entertainment Distribution segment. Its leveraged balance sheet remains a concern. Disney+ is facing tough competition from the likes of Netflix and Amazon Prime Video.
(You can read the full research report on Walt Disney here >>>)
FitLife Brands’ shares have outperformed the Zacks Medical - Products industry over the year-to-date period (+74.5% vs. +12.7%). This microcap company with market capitalization of $152.62 million have witnessed 14.7% year-over-year revenue increase in second-quarter 2024, driven by a 17.5% rise in wholesale and 13.3% in online sales.
Strategic acquisitions and a shift to online channels, now two-thirds of revenue, boosted margins to 44.8%. Key acquisitions like Mimi’s Rock and MusclePharm contribute to growth, with MusclePharm revenues up 27.3% sequentially and Mimi’s Rock’s gross margin at 48.2%, though integration risks remain. The company’s low net debt of $11.7 million supports financial flexibility.
However, challenges include declining legacy brand revenues, a 2.2% drop in the MRC segment, and heavy reliance on online sales, posing risks if e-commerce trends shift. High debt and competition in a saturated market also pose concerns.
(You can read the full research report on FitLife Brands here >>>)
Shares of Utah Medical Products have underperformed the Medical - Products industry over the past six months (-0.2% vs. +7.0%). This microcap company with market capitalization of $236.34 million is facing challenges from declining revenues, particularly with the Filshie Clip System and significant sales drops to PendoTECH, a key customer.
Additionally, foreign exchange risks, increased litigation costs and competitive pressures could further impact UTMD’s financial performance, potentially leading to market share erosion. Nevertheless, a strong balance sheet with $89.2 million in cash and no debt as of June 30, 2024, providing flexibility for strategic investments, acquisitions, or shareholder returns.
The global medical devices market is growing, with UTMD well-positioned to benefit due to its diverse product portfolio in obstetrics, gynecology, neonatal care and blood pressure monitoring. The company’s disciplined cost management reduced COGS and operating expenses, supporting financial stability. UTMD’s focus on niche markets offers strategic advantages, although it.
(You can read the full research report on Utah Medical Products here >>>)
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks Investment Research
Wednesday, August 28, 2024
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. , AstraZeneca PLC and The Walt Disney Co. , as well as two micro-cap stocks FitLife Brands, Inc. and Utah Medical Products, Inc. . The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Visa have gained +4.6% over the year-to-date against the Zacks Financial Transaction Services industry’s gain of +7.9%. The company’s strategic acquisitions and alliances are fostering long-term growth and consistently driving its revenues. Visa, fueled by persistent increases in payments, cross-border volumes and sustained investments in technology, is witnessing significant profit growth.
The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value.
However, elevated operating expenses pose margin challenges. It is witnessing a volatile cash volume from the Asia Pacific and CEMEA regions. Consumer spending growth is also drying up. Moreover, rising client incentives will affect its adjusted revenues. As such, the stock warrants a cautious stance.
(You can read the full research report on Visa here >>>)
AstraZeneca’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+32.3% vs. +29.1%). The company has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra, Ultomiris and Farxiga should keep driving revenues.
AstraZeneca’s pipeline is strong, with important late as well as mid-stage pipeline data readouts lined up. It has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets.
Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. By 2030, it expects to generate $80 billion in total revenues. However, AstraZeneca’s diabetes franchise faces stiff competition while pricing pressure hurts sales in the respiratory unit.
(You can read the full research report on AstraZeneca here >>>)
Shares of Walt Disney have outperformed the Zacks Media Conglomerates industry over the year-to-date period (+0.3% vs. +0.1%). The company’s third-quarter fiscal 2024 results reflect growth in Disney+ subscribers and theme park and resort businesses.
Recent attractions like the Frozen theme land at Hong Kong Disneyland and Walt Disney Park in Paris, as well as the Zootopia theme land at Shanghai Disney, are expected to boost the prospects of the theme park business.
At the same time, the company’s declining ad revenues due to fewer impressions have been a headwind for some time now. Disney+’s profitability is expected to be hurt by higher investments in content, which will also increase programming and production costs in the Media and Entertainment Distribution segment. Its leveraged balance sheet remains a concern. Disney+ is facing tough competition from the likes of Netflix and Amazon Prime Video.
(You can read the full research report on Walt Disney here >>>)
FitLife Brands’ shares have outperformed the Zacks Medical - Products industry over the year-to-date period (+74.5% vs. +12.7%). This microcap company with market capitalization of $152.62 million have witnessed 14.7% year-over-year revenue increase in second-quarter 2024, driven by a 17.5% rise in wholesale and 13.3% in online sales.
Strategic acquisitions and a shift to online channels, now two-thirds of revenue, boosted margins to 44.8%. Key acquisitions like Mimi’s Rock and MusclePharm contribute to growth, with MusclePharm revenues up 27.3% sequentially and Mimi’s Rock’s gross margin at 48.2%, though integration risks remain. The company’s low net debt of $11.7 million supports financial flexibility.
However, challenges include declining legacy brand revenues, a 2.2% drop in the MRC segment, and heavy reliance on online sales, posing risks if e-commerce trends shift. High debt and competition in a saturated market also pose concerns.
(You can read the full research report on FitLife Brands here >>>)
Shares of Utah Medical Products have underperformed the Medical - Products industry over the past six months (-0.2% vs. +7.0%). This microcap company with market capitalization of $236.34 million is facing challenges from declining revenues, particularly with the Filshie Clip System and significant sales drops to PendoTECH, a key customer.
Additionally, foreign exchange risks, increased litigation costs and competitive pressures could further impact UTMD’s financial performance, potentially leading to market share erosion. Nevertheless, a strong balance sheet with $89.2 million in cash and no debt as of June 30, 2024, providing flexibility for strategic investments, acquisitions, or shareholder returns.
The global medical devices market is growing, with UTMD well-positioned to benefit due to its diverse product portfolio in obstetrics, gynecology, neonatal care and blood pressure monitoring. The company’s disciplined cost management reduced COGS and operating expenses, supporting financial stability. UTMD’s focus on niche markets offers strategic advantages, although it.
(You can read the full research report on Utah Medical Products here >>>)
Other noteworthy reports we are featuring today include Sony Group Corp. , BP p.l.c. and Canadian National Railway Co. .
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Visa Rides On Growing Cross Border Volume, Expenses High
Key Drugs Aid AstraZeneca Sales; Pipeline Strong
Disney Banks on Disney+, Theme Parks Business Growth
Featured Reports
SONY Rides on Solid Demand From Music & G&NS Businesses
Per the Zacks analyst, momentum in the Game & Network Services and Music segments cushions Sony's performance. It remains wary of FX volatility and the possibility of an economic downturn in the U.S.
Dividends & Buyback Aid Canadian National , Expenses Ail
The Zacks analyst likes the shareholder-friendly measures adopted by Canadian National. However, rising operating expenses are concerning as they are likely to keep the bottom line under pressure.
Kimberly-Clark Benefits From Gross Supply Chain Productivity
Per the Zacks analyst, Kimberly-Clark is taking robust steps to lower costs. Through the first half of 2024, the company has generated approximately $250 million in gross supply chain productivity.
BFS Tool Aids Builders FirstSource , Low Margin Ails
Per the Zacks analyst, Builders FirstSource benefits from its new BFS digital Tool and a strong value-added product portfolio. Yet, weakening multi-family housing market is denting margins.
Penumbra Rides on Thrombectomy Sales, Global Growth
Penumbra's Thrombectomy growth globally is an upside. Per the Zacks analyst, differentiated technologies of Lightning Flash 2 and Lightning Bolt 7 leading to strong patient outcomes is a key driver.
Rezdiffra Sales Boosts Madrigal , Narrow Pipeline a Woe
Per the Zacks Analyst, the approval of Rezdiffra for NASH is a huge boost for Madrigal ensuring a regular revenue stream. However, the lack of a deep pipeline is a woe.
Operational Efficiency Aids Silgan Amid Low Prices
Per the Zacks analyst, Silgan is gaining from a disciplined capital allocation model and a strong operational performance. Lower prices will hurt its top line.
New Upgrades
BP's Robust Upstream Portfolio To Boost Production Capacity
Per the Zacks analyst, BP's portfolio of upstream projects continues to grow with the beginning of major projects like Seagull. However, its significant reliance on debt capital raises concern.
Sprouts Farmers' Omnichannel Offering to Propel Sales
Per the Zacks analyst, Sprouts Farmers' ability to deliver a seamless omnichannel experience enhances customer loyalty. E-commerce sales rose 30% in the second quarter, representing 14% of net sales.
SM Energy's Robust Eagle Ford & Permian Presence Aids
Per the Zacks analyst, SM Energy's strategic expansion in Texas, particularly in the Permian and Eagle Ford regions, signals growth, leveraging its assets to capitalize on crude price uptrends.
New Downgrades
Weak Industrial Segment and Increasing Costs Ail Barnes
Per the Zacks analyst, Barnes is experiencing softness in the Industrial unit due to softness in the motion control solutions and automation businesses. High costs are an added concern.
Elevated Expenses Likely to Mar Atlassian's Margins
Per the Zacks analyst, increased investment toward enhancing sales & marketing capabilities and higher spending on research & development are likely to dampen Atlassian's margins in the near term.
Macerich Hurt by Tenant Bankruptcies & E-Commerce Adoption
Per the Zacks Analyst, MAC's performance is likely to be affected by tenant bankruptcies, growing adoption of online shopping and substantial geographic concentration of assets.n
Zacks Investment Research
FitLife Brands just reported results for the second quarter of 2024.
InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com.
More from InvestorPlace
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.